MAX BioPharma and Revilico Collaboration LOS ANGELES, CA / ACCESS Newswire / August 6, 2025 / Today MAX BioPharma, Inc. ( and Revilico, Inc. ( announced their collaboration in studying the mechanisms ...

SkyQuest Technology Consulting published a report, titled, Biomarkers Market - Global Opportunity Analysis and Industry ...

Eko Health, a leader in AI-powered cardiac and pulmonary care, announced the expansion of its Clinical Advisory Board to ...

Revvity, Inc. (NYSE: RVTY), today announced the launch of pHSense™ reagents, a powerful technology designed to advance ...

Q2 2025 Earnings Call Transcript August 4, 2025 Castle Biosciences, Inc. beats earnings expectations. Reported EPS is $0.15, ...

Overview of Cell Isolation MarketThe global Cell Isolation Market is valued at USD 15.6 Billion in 2024 and is projected to reach a value of USD 60.56 Billion by 2035 at a CAGR (Compound Annual Growth ...

Moderate exercise may slow brain aging, protecting cognition and brain structure, while too little or too much activity may ...

Senolytic Supplements Market to Reach $350 Million by 2025, Poised for 15% CAGR Through 2032 Driven by growing focus on healthy aging and breakthroughs in cellular senescence-targeted therapies The ...

HOXB13, a B-class homeobox transcription factor, sits at the hub of developmental gene networks yet has emerged as a ...

HOXB13, a B-class homeobox transcription factor, sits at the hub of developmental gene networks yet has emerged as a ...

HOXB13, a B-class homeobox transcription factor, sits at the hub of developmental gene networks yet has emerged as a double-edged sword in human cancer.

About one quarter of patients with muscle-invasive bladder cancer (MIBC) may be treated and derive a benefit with the current standard chemotherapy. To better understand why some tumors resist chemoth ...